​

CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

OverviewForecastRevenueFinancialsChart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 3.86% institutional investors, 1.75% insiders, and 94.39% retail investors. Ark investment management is the largest institutional shareholder, holding 10.53% of CRSP shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.37% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCRISPR Therapeutics3.86%1.75%94.39%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management8.97M10.53%$353.18M
Capital investors8.74M10.26%$344.15M
T. rowe price investment management3.81M4.47%$150.03M
Blackrock2.78M3.40%$150.03M
Blackrock funding, inc. /de2.76M3.24%$108.61M
Sumitomo mitsui trust2.75M3.22%$108.07M
Nikko asset management americas2.75M3.22%$108.07M
State street2.49M2.95%$98.07M
Fmr2.22M2.61%$87.51M
Ubs group1.98M2.33%$78.09M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management498.56K22.62%$19.62M
Sr one capital management, lp1.05M10.07%$41.29M
Spear rsc165.00K6.29%$8.91M
Nea management company1.59M4.16%$54.03M
Ark investment management8.97M2.94%$353.18M
Contrarius investment management685.72K2.32%$37.04M
Ecor1 capital1.39M2.07%$54.68M
Eagle health investments lp197.00K1.87%$10.64M
Nikko asset management americas2.75M1.17%$108.07M
Green alpha advisors24.63K0.78%$969.40K

Top Buyers

HolderShares% AssetsChange
Orbis allan gray1.48M0.31%1.48M
Ark investment management8.97M2.94%1.47M
Ubs group1.98M0.01%1.31M
T. rowe price investment management3.81M0.09%1.07M
Capital investors8.74M0.06%816.79K

Top Sellers

HolderShares% AssetsChange
Baker bros. advisors lp654.10K0.25%-653.91K
Bellevue group---610.00K
Farallon capital management---530.00K
State street2.49M0.00%-501.46K
Morgan stanley597.68K0.00%-488.25K

New Positions

HolderShares% AssetsChangeValue
Orbis allan gray1.48M0.31%1.48M$58.10M
Norges bank443.54K0.00%443.54K$17.46M
Susquehanna fundamental investments92.39K0.05%92.39K$3.64M
Imc-chicago86.47K0.00%86.47K$3.40M
Raymond james financial82.09K0.00%82.09K$3.23M

Sold Out

HolderChange
Impact partnership wealth-1.00
Activest wealth management-1.00
Toronto dominion bank-4.00
Baldwin brothers llc/ma-4.00
Financial gravity asset management-5.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202516-96.30%3,317,986-94.86%30.07%8-95.58%3-97.52%
Dec 31, 2024420-5.83%64,513,2688.48%761.57%174-118-10.61%
Sep 30, 2024437-9.15%59,424,788-0.24%691.31%167-19.71%1311.55%
Jun 30, 2024478-7.54%59,547,6001.78%721.42%205-12.02%129-9.15%
Mar 31, 20245170.58%58,507,2425.59%711.48%233-10.73%14215.45%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite7.18M8.37%743.79K
ARK Innovation ETF6.96M8.05%220.37K
American Funds New Perspective A2.55M2.98%-2.24M
Capital Group New Perspective Comp2.55M2.96%-2.24M
ARK Genomic Revolution2.09M2.44%299.75K
ARK Genomic Revolution ETF2.04M2.36%32.01K
American Funds SMALLCAP World A1.65M1.91%28.38K
SPDR® S&P Biotech ETF1.65M1.91%2.13K
T. Rowe Price Mid-Cap Growth1.49M1.74%-1.80K
T. Rowe Price US Mid-Cap Growth Equity1.49M1.73%-2.40K

Recent Insider Transactions

DateNameRoleActivityValue
May 29, 2025Patel Naimish Chief Medical OfficerSell$141.32K
Mar 21, 2025Kulkarni Samarth Chief Executive OfficerSell$413.58K
Mar 21, 2025Bruno Julianne Chief Operating OfficerSell$70.67K
Mar 21, 2025Prasad Raju Chief Financial OfficerSell$90.58K
Mar 21, 2025KASINGER JAMES R. General Counsel and SecretarySell$131.32K

Insider Transactions Trends

DateBuySell
2025 Q2-1
2025 Q1117
2024 Q4-5
2024 Q3--
2024 Q2-3

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 3.86%, followed by 1.75% insiders and 94.39% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 63.96%, which CRISPR Therapeutics falls below.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (8.97M shares, 10.53%), Capital investors (8.74M shares, 10.26%), and T. rowe price investment management (3.81M shares, 4.47%). Together, they hold 25.26% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 22.62% of its assets in 498.56K CRISPR Therapeutics shares, valued at 19.62M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of CRISPR Therapeutics shares, with 8.37% of its total shares outstanding invested in 7.18M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools